Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   BASIC AND CLINICAL NEUROSCIENCE   FALL 2011 , Volume 3 , Number 1; Page(s) 48 To 57.
 
Paper: 

VARENICLINE AMELIORATES LEARNING AND MEMORY DEFICITS IN AMYLOID β (25–35) RAT MODEL OF ALZHEIMER’S DISEASE

 
 
Author(s):  BALUCHNEJADMOJARAD TOURANDOKHT*, ROGHANI MEHRDAD, KARIMI NARGES, KAMRAN MITRA
 
* DEPARTMENT OF PHYSIOLOGY, SCHOOL OF MEDICINE, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

Introduction: Alzheimer’s disease (AD) is a enfeeble neurodegenerative disorder characterized by increased b-amyloid (Ab) deposition and neuronal dysfunction leading to impaired learning and recall. Among proposed risk factors, impaired cholinergic transmission is a main cause for incidence of disease.
Methods: In the present study, effects of the intracerebroventricularly administration of an agonist of nicotinic cholinergic receptors, varenicline (0.5 and 2
mg/ml), on learning and memory impairments induced by intrahippocampal Ab (25–35) injection was assessed in rats.
Results: The results showed that the intrahippocampal A
b (25–35) injected rats exhibit lower spontaneous alternation score inY-maze tasks (p<0.05), impaired retention and recall capability in the passive avoidance test (p<0.05), and fewer correct choices (p<0.001) and more errors (p<0.001) in the RAM task. Varenicline, almost in both doses, significantly improved alternation score in Y-maze task (p<0.001), impaired retention and recall capability in the passive avoidance test (p<0.05), and correct choices in the RAM task (p<0.001).
Discussion: This study indicates that varenicline pretreatment attenuates Ab-induced impairment of short-term spatial memory in rats probably due to its agonist activity at nicotinic receptors.

 
Keyword(s): Aβ (25–35), VARENICLINE, PASSIVE AVOIDANCE, Y MAZE, RADIAL MAZE, RAT
 
References: 
  • ندارد
 
  Yearly Visit 68
 
Latest on Blog
Enter SID Blog